Vanguard Group Inc Verastem, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.33 - $10.44 $1,336 - $42,271	4,049 Added 0.05%	8,515,562 $3.41 Million
Q3 2022 Nov 14, 2022	BUY	$0.92 - $11.16 $485,780 - $5.89 Million	528,022 Added 6.61%	8,511,513 $7.24 Million
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $837,822 - $1.5 Million	-821,395 Reduced 9.33%	7,983,491 $9.26 Million
Q1 2022 May 13, 2022	SELL	$1.06 - $2.1 $47,604 - $94,311	-44,910 Reduced 0.51%	8,804,886 $12.4 Million
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $341,960 - $533,792	-166,810 Reduced 1.85%	8,849,796 $18.1 Million
Q3 2021 Nov 12, 2021	BUY	$2.54 - $4.07 $639,323 - $1.02 Million	251,702 Added 2.87%	9,016,606 $27.8 Million
Q2 2021 Aug 13, 2021	BUY	$2.57 - $4.85 $22.5 Million - $42.5 Million	8,764,904 New	8,764,904 $35.7 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.25B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.